Success Metrics

Clinical Success Rate
89.3%

Based on 25 completed trials

Completion Rate
89%(25/28)
Active Trials
1(3%)
Results Posted
60%(15 trials)
Terminated
3(9%)

Phase Distribution

Ph early_phase_1
1
3%
Ph not_applicable
3
9%
Ph phase_2
10
29%
Ph phase_1
5
15%
Ph phase_3
2
6%
Ph phase_4
12
35%

Phase Distribution

6

Early Stage

10

Mid Stage

14

Late Stage

Phase Distribution33 total trials
Early Phase 1First-in-human
1(3.0%)
Phase 1Safety & dosage
5(15.2%)
Phase 2Efficacy & side effects
10(30.3%)
Phase 3Large-scale testing
2(6.1%)
Phase 4Post-market surveillance
12(36.4%)
N/ANon-phased studies
3(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.6%

25 of 31 finished

Non-Completion Rate

19.4%

6 ended early

Currently Active

1

trials recruiting

Total Trials

34

all time

Status Distribution
Active(1)
Completed(25)
Terminated(6)
Other(2)

Detailed Status

Completed25
Terminated3
Withdrawn3
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
34
Active
1
Success Rate
89.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.0%)
Phase 15 (15.2%)
Phase 210 (30.3%)
Phase 32 (6.1%)
Phase 412 (36.4%)
N/A3 (9.1%)

Trials by Status

recruiting13%
terminated39%
completed2574%
unknown26%
withdrawn39%

Recent Activity

1 active trials
Showing 5 of 34
recruitingphase_2

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

NCT07060638
completedphase_4

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

NCT03818191
withdrawnphase_2

Acamprosate and Methazolamide for Essential Tremor

NCT06312800
completedphase_2

Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations

NCT06471686
withdrawnphase_4

Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)

NCT00655967
View all 34 trials

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT07060638Phase 2

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Recruiting
NCT03818191Phase 4

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

Completed
NCT06312800Phase 2

Acamprosate and Methazolamide for Essential Tremor

Withdrawn
NCT06471686Phase 2

Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations

Completed
NCT00655967Phase 4

Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)

Withdrawn
NCT02998151Early Phase 1

Neurophysiological and Acute Pharmacological Studies in FXS Patients

Completed
NCT01813318Phase 1

Study of Acamprosate in Autism

Completed
NCT01911455Phase 1

Study of Acamprosate in Fragile x Syndrome

Completed
NCT04498897Phase 2

Vortioxetine for Treatment of Depressive Mood and Alcohol Use

Unknown
NCT00385268Phase 2

Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence

Completed
NCT00463346Phase 3

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

Completed
NCT00688324Phase 4

Biomarker Study of Acamprosate in Schizophrenia

Completed
NCT01300923Phase 2

Acamprosate in Youth With Fragile X Syndrome

Completed
NCT00466661Phase 4

Acamprosate vs. Placebo in Bipolar Alcoholics

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT00571103Phase 4

Acamprosate in the Treatment of Pathological Gambling

Completed
NCT00656630Phase 2

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

Completed
NCT00571922Phase 1

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction

Completed
NCT00360594Phase 2

Acamprosate Initiated During Alcohol Detoxification

Completed
NCT00596531Phase 1

Clinical Trial of Acamprosate for Tinnitus

Completed

Drug Details

Intervention Type
DRUG
Total Trials
34